Skin Cancer - Wesley Research Institute

This project aims to find new biomarkers for immunotherapy in patients with melanoma.

Research Objectives

Status

Current

Recruitment

Open

Study location

Wesley Research Insitute, The Wesley Hospital

Study type

Industry Sponsored

Patient group

Cancer – Stage IV Melanoma

About this clinical trial

Cancer immunotherapy has been shown to provide patients with an excellent new type of treatment and is in common use world-wide. Unfortunately, we know that not all patients will respond to their immunotherapy treatment in the same way.

Responses to immunotherapy may be affected by a patient’s microbiome, or the community of bacteria that live in their bowel. This group of bacteria can influence the immune system by increasing or decreasing certain types of white cells, called T cells that are produced in the body. By analysing the bacteria, this project aims to find new biomarkers for immunotherapy in patients with melanoma.

Finding new biomarkers for immunotherapy in patients with melanoma

Technical title

Metabolomics in Enhancing Responses to Cancer ImmunoTherapy in Melanoma (MERIT-M)

Register your interest

If you would like more information about this clinical trial, please complete the contact form below.

Name(Required)

Email(Required)

Phone*(Required)

Date(Required)

Would you like to be updated on the progress of our research?(Required)

Yes

No

Message

CAPTCHA

I consent to receive updates on Wesley Research Institute news and events, clinical trials, research projects and how to support WRI.

Yes

By submitting this form you consent for us to hold your information in accordance with our Privacy Policy

Name

This field is for validation purposes and should be left unchanged.